{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T14:43:53Z","timestamp":1787496233294,"version":"build-2736575974"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004484","name":"Tehran University of Medical Sciences and Health Services","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004484","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.msard.2025.106609","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T16:39:43Z","timestamp":1752597583000},"page":"106609","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Prevalence and distribution of HPV genotypes in female patients with multiple sclerosis"],"prefix":"10.1016","volume":"102","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4669-3303","authenticated-orcid":false,"given":"Mojtaba","family":"Shahbazi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Kaeedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanaz Heydari","family":"Havadaragh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Ranjbar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjan","family":"Farhadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahsa","family":"Doomanlou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narges","family":"Zamani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atefeh Eidi","family":"Ardizi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samaneh","family":"Kabiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ehsan","family":"Mohammadianinejad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Hossein","family":"Harirchian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2025.106609_bib0001","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.msard.2018.04.018","article-title":"HPV-related papillary squamous cell carcinoma of the tonsil during treatment with fingolimod","volume":"23","author":"Benedetti","year":"2018","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"12","key":"10.1016\/j.msard.2025.106609_bib0002","first-page":"13","article-title":"Prevalence and distribution of HPV Genotypes in immunosuppressed patients in lorraine region","author":"Boudes","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.msard.2025.106609_bib0003","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2023.1119660","article-title":"Risk of cervical pre-cancer and cancer in women with multiple sclerosis exposed to high efficacy disease modifying therapies","volume":"14","author":"Bridge","year":"2023","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2025.106609_bib0004","doi-asserted-by":"crossref","DOI":"10.1136\/jnnp-2022-329223","article-title":"Superior effects of natalizumab versus other DMTs on patient-reported outcomes in people with multiple sclerosis","author":"Chen","year":"2022","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"9","key":"10.1016\/j.msard.2025.106609_bib0005","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1093\/cid\/cix135","article-title":"Carcinogenicity of human papillomavirus (HPV) types in HIV-positive women: a meta-analysis from HPV infection to cervical cancer","volume":"64","author":"Clifford","year":"2017","journal-title":"Clin. Infect. Dis."},{"issue":"1","key":"10.1016\/j.msard.2025.106609_bib0006","first-page":"28","article-title":"HPV-associated anal and genital intraepithelial neoplasia after using fingolimod in the treatment of relapsing-remitting multiple sclerosis: a case report","volume":"2","author":"Doganay Ocalan","year":"2022","journal-title":"J. Mult. Scler Res."},{"key":"10.1016\/j.msard.2025.106609_bib0007","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1150238","article-title":"Human papillomavirus vaccination in low- and middle-income countries: progression, barriers, and future prospective","volume":"14","author":"Ebrahimi","year":"2023","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.msard.2025.106609_bib0008","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1056\/NEJMoa0909537","article-title":"Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males","volume":"364","author":"Giuliano","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2025.106609_bib0009","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.pharmthera.2017.11.001","article-title":"The sphingosine 1-phosphate receptor modulator fingolimod as a therapeutic agent: recent findings and new perspectives","volume":"185","author":"Huwiler","year":"2018","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.msard.2025.106609_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2019.101437","article-title":"Skin warts during fingolimod treatment in patients with multiple sclerosis","volume":"36","author":"Jaafar","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"1","key":"10.1016\/j.msard.2025.106609_bib0011","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1586\/14737175.2016.1123094","article-title":"Fingolimod: a review of its mode of action in the context of its efficacy and safety profile in relapsing forms of multiple sclerosis","volume":"16","author":"Jeffery","year":"2016","journal-title":"Expert. Rev. NeurOther"},{"key":"10.1016\/j.msard.2025.106609_bib0012","series-title":"CADTH Rapid Response Reports Second-Line Therapy for Patients with Relapsing-Remitting Multiple Sclerosis: A Review of Guidelines","author":"Li","year":"2019"},{"issue":"8","key":"10.1016\/j.msard.2025.106609_bib0013","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1001\/jama.2020.26858","article-title":"Diagnosis and treatment of multiple sclerosis: a review","volume":"325","author":"McGinley","year":"2021","journal-title":"JAMa"},{"key":"10.1016\/j.msard.2025.106609_bib0014","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.3389\/fimmu.2019.02954","article-title":"Multiple sclerosis and cancer: the ying-yang effect of disease modifying therapies","volume":"10","author":"Melamed","year":"2019","journal-title":"Front. Immunol."},{"issue":"11","key":"10.1016\/j.msard.2025.106609_bib0015","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1177\/1352458521991433","article-title":"Human papillomavirus lesions in 16 MS patients treated with fingolimod: outcomes and vaccination","volume":"27","author":"Mhanna","year":"2021","journal-title":"Mult. Scler."},{"issue":"3","key":"10.1016\/j.msard.2025.106609_bib0016","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1177\/1352458520952311","article-title":"The risk of infection in patients with multiple sclerosis treated with disease-modifying therapies: a Delphi consensus statement","volume":"27","author":"Moiola","year":"2021","journal-title":"Mult. Scler."},{"issue":"35","key":"10.1016\/j.msard.2025.106609_bib0017","doi-asserted-by":"crossref","first-page":"5215","DOI":"10.1016\/j.vaccine.2012.06.013","article-title":"Prevalence of type-specific human papillomavirus infection among women in France: implications for screening, vaccination, and a future generation of multivalent HPV vaccines","volume":"30","author":"Monsonego","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.msard.2025.106609_bib0018","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/B978-0-444-52001-2.00022-4","article-title":"Immunosuppressive treatments in multiple sclerosis","volume":"122","author":"Okuda","year":"2014","journal-title":"Handb. Clin. Neurol."},{"issue":"8","key":"10.1016\/j.msard.2025.106609_bib0019","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.neurol.2021.04.011","article-title":"Infections and multiple sclerosis: recommendations from the French Multiple Sclerosis Society","volume":"177","author":"Papeix","year":"2021","journal-title":"Rev. Neurol. (Paris)"},{"key":"10.1016\/j.msard.2025.106609_bib0020","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2023.1073278","article-title":"Global, regional, and national burden of multiple sclerosis from 1990 to 2019: findings of global burden of disease study 2019","volume":"11","author":"Qian","year":"2023","journal-title":"Front. Public Health"},{"issue":"1","key":"10.1016\/j.msard.2025.106609_bib0021","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13027-022-00421-7","article-title":"Prevalence of human papilloma virus (HPV) genotypes between outpatients males and females referred to seven laboratories in Tehran, Iran","volume":"17","author":"Rezaee Azhar","year":"2022","journal-title":"Infect. Agent. Cancer"},{"issue":"8","key":"10.1016\/j.msard.2025.106609_bib0022","doi-asserted-by":"crossref","first-page":"673","DOI":"10.2165\/11207350-000000000-00000","article-title":"Fingolimod: a review of its use in the management of relapsing-remitting multiple sclerosis","volume":"25","author":"Scott","year":"2011","journal-title":"CNS. Drugs"},{"issue":"2","key":"10.1016\/j.msard.2025.106609_bib0023","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol."},{"issue":"11","key":"10.1016\/j.msard.2025.106609_bib0024","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1177\/1352458518807088","article-title":"Warts and all: fingolimod and unusual HPV-associated lesions","volume":"25","author":"Triplett","year":"2019","journal-title":"Mult. Scler."},{"issue":"2","key":"10.1016\/j.msard.2025.106609_bib0025","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.nic.2016.12.001","article-title":"Multiple sclerosis: epidemiologic, clinical, and therapeutic aspects","volume":"27","author":"Vidal-Jordana","year":"2017","journal-title":"NeuroimAging Clin. N. Am."},{"issue":"4","key":"10.1016\/j.msard.2025.106609_bib0026","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.ogc.2008.09.006","article-title":"Natural history of human papillomavirus infections, cytologic and histologic abnormalities, and cancer","volume":"35","author":"Wheeler","year":"2008","journal-title":"Obstet. Gynecol. Clin. North Am."},{"key":"10.1016\/j.msard.2025.106609_bib0027","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1159\/000357907","article-title":"Human papillomavirus and immunosuppression","volume":"45","author":"Wieland","year":"2014","journal-title":"Curr. Probl. Dermatol."},{"issue":"4","key":"10.1016\/j.msard.2025.106609_bib0028","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nrneurol.2016.21","article-title":"Disease-modifying therapies and infectious risks in multiple sclerosis","volume":"12","author":"Winkelmann","year":"2016","journal-title":"Nat. Rev. Neurol."},{"issue":"4","key":"10.1016\/j.msard.2025.106609_bib0029","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1111\/bcp.14198","article-title":"The efficacy and safety of fingolimod in patients with relapsing multiple sclerosis: a meta-analysis","volume":"86","author":"Yang","year":"2020","journal-title":"Br. J. Clin. Pharmacol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825003517?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825003517?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T07:23:41Z","timestamp":1780039421000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034825003517"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":29,"alternative-id":["S2211034825003517"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2025.106609","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prevalence and distribution of HPV genotypes in female patients with multiple sclerosis","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2025.106609","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106609"}}